Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) Research & Development (2023 - 2025)

Rallybio (RLYB) has disclosed Research & Development for 3 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 50.51% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.6 million through Dec 2025, down 52.79% year-over-year, with the annual reading at $19.6 million for FY2025, 52.79% down from the prior year.
  • Research & Development hit $3.7 million in Q4 2025 for Rallybio, down from $4.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $15.9 million in Q4 2023 to a low of $3.7 million in Q4 2025.
  • Historically, Research & Development has averaged $9.6 million across 3 years, with a median of $9.7 million in 2023.
  • Biggest five-year swings in Research & Development: increased 15.48% in 2024 and later plummeted 55.74% in 2025.
  • Year by year, Research & Development stood at $15.9 million in 2023, then tumbled by 53.62% to $7.4 million in 2024, then plummeted by 50.51% to $3.7 million in 2025.
  • Business Quant data shows Research & Development for RLYB at $3.7 million in Q4 2025, $4.1 million in Q3 2025, and $6.1 million in Q2 2025.